Skip to content

Pharmacogenetics of Cannabinoid Response

Pharmacogenetics of Cannabinoid Response

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00678730
Enrollment
72
Registered
2008-05-15
Start date
2007-08-23
Completion date
2014-09-11
Last updated
2022-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COMT Gene Polymorphism

Keywords

THC, COMT gene polymorphism, schizophrenia, cannabis use

Brief summary

This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, ganja, or pot.

Interventions

0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 and 55 years (extremes included) on the day of the first dosing.

Exclusion criteria

* Cannabis naïve individuals.

Design outcomes

Primary

MeasureTime frame
Behavioral MeasuresBaseline, +15, +25, +60, +300

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026